Trupanion Inc (NYSE:TRUP) Director Howard E. Rubin sold 8,706 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $17.00, for a total value of $148,002.00. Following the sale, the director now owns 41,294 shares in the company, valued at approximately $701,998. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Trupanion Inc (NYSE:TRUP) traded down 1.41% during mid-day trading on Wednesday, hitting $16.75. The stock had a trading volume of 91,550 shares. The firm’s market cap is $489.99 million. Trupanion Inc has a 52-week low of $7.61 and a 52-week high of $17.68. The stock’s 50-day moving average price is $16.12 and its 200-day moving average price is $15.19.

Trupanion (NYSE:TRUP) last posted its earnings results on Tuesday, November 1st. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). The business earned $48.40 million during the quarter, compared to the consensus estimate of $48.17 million. The firm’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.17) earnings per share. On average, analysts anticipate that Trupanion Inc will post ($0.23) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Trupanion (NYSE:TRUP)

Several equities research analysts recently commented on the company. Stifel Nicolaus upped their target price on Trupanion from $17.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Canaccord Genuity restated a “buy” rating and set a $19.00 target price on shares of Trupanion in a research report on Thursday, August 4th. RBC Capital Markets restated an “outperform” rating and set a $18.00 target price (up previously from $14.00) on shares of Trupanion in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research lowered Trupanion from a “buy” rating to a “hold” rating in a research report on Wednesday, July 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.00.

Hedge funds have recently bought and sold shares of the company. Hamilton Lane Advisors LLC acquired a new stake in Trupanion during the second quarter valued at about $1,657,000. Monashee Investment Management LLC purchased a new stake in Trupanion during the second quarter valued at $245,000. RMB Capital Management LLC purchased a new stake in Trupanion during the second quarter valued at $1,642,000. Emerald Acquisition Ltd. purchased a new stake in Trupanion during the second quarter valued at $529,000. Finally, California Public Employees Retirement System boosted its stake in Trupanion by 80.4% in the second quarter. California Public Employees Retirement System now owns 45,100 shares of the company’s stock valued at $598,000 after buying an additional 20,100 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/23/trupanion-inc-trup-director-howard-e-rubin-sells-8706-shares.html.

About Trupanion

Trupanion, Inc provides a medical insurance plan for cats and dogs across the United States, Canada and Puerto Rico. The Company operates through two segments: subscription business and other business. The subscription business segment includes monthly subscriptions related to the Company’s medical plan, which are marketed directly to consumers.

5 Day Chart for NYSE:TRUP

Receive News & Stock Ratings for Trupanion Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion Inc and related stocks with our FREE daily email newsletter.